4-methyl-2-(trifluoromethyl)penta-1,3-diene

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 4-methyl-2-(trifluoromethyl)penta-1,3-diene
• 英文别名: 4-Methyl-2-trifluoromethylpentadiene
• 化学式: C₇H₉F₃
• 分子量: 150.144
• InChiKey: OFCQRWAGTANYTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tetrachlorobis(2,7-dimethyl-2,6-octadienylene)diruthenium 、 4-methyl-2-(trifluoromethyl)penta-1,3-diene 在 lithium carbonate 作用下， 以 乙醇 为溶剂， 以18.8 %的产率得到
  参考文献：
  名称：

  US2022/372056

  摘要：

  公开号：

文献信息

• [EN] NOVEL HETEROCYCLIC DERIVATIVES AS MODULATORS OF KINASE ACTIVITY<br/>[FR] NOUVEAUX DÉRIVÉS HÉTÉROCYCLIQUES COMME MODULATEURS DE L'ACTIVITÉ KINASE
  申请人：MERCK PATENT GMBH

  公开号：WO2014078637A1

  公开（公告）日：2014-05-22

  The invention provides novel imidazol-piperidinyl derivatives of the formula (I) in which R1, R2, W, X1, X2, X3, X4 and n have the meanings indicated in formula (I), and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.

  该发明提供了公式（I）中的新型咪唑-哌啶衍生物，其中R1、R2、W、X1、X2、X3、X4和n具有公式（I）中所示的含义，并且它们的制造和用于治疗高增殖性疾病，如癌症。
• [EN] PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS<br/>[FR] INHIBITEURS DE LA PROTÉASE POUR LE TRAITEMENT D'INFECTIONS À CORONAVIRUS
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2022261473A1

  公开（公告）日：2022-12-15

  The application relates to compounds of Formula (I) and (III), their pharmaceutically acceptable salts, and their pharmaceutical compositions. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and they are useful in treating or preventing COVID-19 in a subject.

  该申请涉及(I)和(III)式化合物及其药学上可接受的盐和制药组合物。这些化合物是严重急性呼吸综合症冠状病毒2号(SARS-CoV-2)的主要蛋白酶(Mpro)的有效抑制剂，并可用于治疗或预防受COVID-19感染的个体。
• Inhibiting human integrin (alpha-4) (beta-7)
  申请人：Morphic Therapeutic, Inc.

  公开号：US11370773B1

  公开（公告）日：2022-06-28

  Disclosed are small molecule antagonists of human α4β7 integrin, and methods of using them to treat a number of diseases and conditions.

  所公开的是人类 α4β7 整合素的小分子拮抗剂，以及用它们治疗多种疾病和病症的方法。
• PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP3192511B1

  公开（公告）日：2021-07-14
• [EN] SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES D'URÉE PONTÉS SUBSTITUÉS EN TANT QUE MODULATEURS DE SIRTUINE
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2016079711A1

  公开（公告）日：2016-05-26

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. (I)